High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.

摘要: The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook present study to effect on loss seroconversion rates Indian patients CHB relation frequency, predictors durability. treated 60 e antigen positive (with active viral replication ongoing necro-inflammatory activity) with Lamivudine. They were followed up by monthly aminotransferases, 3 anti-HBe. Those who attained advised discontinue after 6 months every thereafter, see for relapse. Treatment was given maximum years if not sero-converted. annual incremental receiving 25 (41.6%) at end 1st year, 33 (55%) 2nd year 35 (58.3%) 3rd year. corresponding full 17/60 (28.6%), 22/60 (36.6%) 24/60 (40%) years. correlated increased pre-therapy ALT levels (p = 0.002) decreased pretreatment HBV-DNA 0.004). presence cirrhosis had no influence loss. Relapse occurred 35% (7/20) median time months. showed a higher first treatment. This baseline inversely levels. treatment high soon stopping